Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
RhoA vesicle trafficking–mediated transglutaminase 2 membrane translocation promotes IgA1 mesangial deposition in IgA nephropathy
Zhong Zhong, Zhijian Li, Yanjie Li, Lanping Jiang, Qingyu Kong, Wei Chen, Shaozhen Feng
Zhong Zhong, Zhijian Li, Yanjie Li, Lanping Jiang, Qingyu Kong, Wei Chen, Shaozhen Feng
View: Text | PDF
Research Article Nephrology

RhoA vesicle trafficking–mediated transglutaminase 2 membrane translocation promotes IgA1 mesangial deposition in IgA nephropathy

  • Text
  • PDF
Abstract

Transglutaminase 2 (TGase2) has been shown to contribute to the mesangial IgA1 deposition in a humanized mouse model of IgA nephropathy (IgAN), but the mechanism is not fully understood. In this study, we found that inhibition of TGase2 activity could dramatically decrease the amount of polymeric IgA1 (pIgA1) isolated from patients with IgAN that interacts with human mesangial cells (HMC). TGase2 was expressed both in the cytosol and on the membrane of HMC. Upon treatment with pIgA1, there were more TGase2 recruited to the membrane. Using a cell model of mesangial deposition of pIgA1, we identified 253 potential TGase2-associated proteins in the cytosolic fraction and observed a higher concentration of cellular vesicles and increased expression of Ras homolog family member A (RhoA) in HMC after pIgA1 stimulation. Both the amount of pIgA1 deposited on HMC and membrane TGase2 level were decreased by inhibition of the vesicle trafficking pathway. Mechanistically, TGase2 was found to be coprecipitated with RhoA in the cellular vesicles. Membrane TGase2 expression was greatly increased by overexpression of RhoA, while it was reduced by knockdown of RhoA. Our in vitro approach demonstrated that TGase2 was transported from the cytosol to the membrane through a RhoA-mediated vesicle-trafficking pathway that can facilitate pIgA1 interaction with mesangium in IgAN.

Authors

Zhong Zhong, Zhijian Li, Yanjie Li, Lanping Jiang, Qingyu Kong, Wei Chen, Shaozhen Feng

×

Figure 4

TGase2 is present in cellular vesicles of plasma membrane origin in HMC.

Options: View larger image (or click on image) Download as PowerPoint
TGase2 is present in cellular vesicles of plasma membrane origin in HMC....
(A) Flowchart of the centrifugation and filtration steps for the isolation of cellular vesicles. S1 and S2 indicate supernatants. S2 is total lysate (TL). C1 indicates purified cellular vesicles. F1 and F2 indicate filtrate. (B) HMC were planted in a 6-well plate overnight and then grown in serum-free medium with supplementation of 10 μg/mL pIgA1 or PBS for 24 hours. Cellular vesicles were purified as shown in A. The microparticle size distribution in fractions C1 from HMC treated with PBS (NC) or pIgA1 was obtained using nanoparticle tracking analysis (n = 3). (C) Expression of FLOT2 and TGase2 in purified cellular vesicles (C1), filtrate fractions (F1 and F2), and cell lysate (TL) from HMC treated with or without pIgA1 were measured by Western blot in equal amounts of proteins from different fractions.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts